

FINANCIAL STATEMENTS (Un-Audited)
For the period from 01.07.2019 to 31.12.2019.



THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,
Dhaka-1207, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207

Honorable Shareholder(s),
Assalamu Alaikum Wa Rahmatullah,

As per rule 13 of Securities and Exchange Rules-1987 and Bangladesh Accounting Standard (BAS) -34, we are pleased to enclose herewith the un-audited Statement of Financial Position as at 31st December 2019, the Statement of Profit or Loss and other Comprehensive Income, Statement of Cash Flows and Statement of Changes in Equity for the half-year ended 31st December, 2019 for your kind perusal.

STATEMENT OF FINANCIAL POSITION (Un-Audited)

As at 31st December, 2019

			Amount in Taka	
Notes	As at 31.12.2019	As at 30.06.2019		
ASSETS:				
Non-Current Assets:				
Property, Plant and Equipment	2,184,151,617	1,864,246,635		
Capital work-in-progress	1,698,701,245	1,684,778,352		
Right of Use of Assets	400,172,699	139,187,479		
Investment in Marketable Securities (AFS)	45,129,994	-		
Investment in associate	4,745,230	4,878,355		
	35,402,449	35,402,449		
Current Assets :				
Inventories	1,045,023,600	964,225,217		
Accounts Receivable	597,811,489	522,185,354		
Advances, Deposits & Prepayments	26,466,517	22,585,997		
Cash & Cash Equivalents	219,592,122	248,500,644		
	201,153,472	170,953,223		
TOTAL ASSETS	3,229,175,217	2,828,471,852		
SHAREHOLDERS' EQUITY AND LIABILITIES:				
Shareholders' Equity:				
Share Capital	1,612,506,356	1,478,296,395		
Net Gain on Marketable Securities (AFS)	312,436,270	312,436,270		
Tax Holiday Reserve	(245,949)	(126,137)		
Retained Earnings	4,392,110	4,392,110		
	1,295,923,925	1,161,594,152		
Non-Current Liabilities				
Lease Liability	232,211,153	125,979,541		
Deferred Tax Liability	46,431,516	-		
	82,646,958	79,884,252		
Current Liabilities:				
Bank & Other Finance	1,255,379,235	1,144,311,663		
Accounts and Other Payables	894,817,928	565,601,655		
	360,561,307	578,710,008		
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	3,229,175,217	2,828,471,852		
Net Asset Value (NAV) per Share	51.61	47.32		

Chief Financial Officer

Company Secretary

Director

Dated, Dhaka
22-Jan-20

Managing Director

Chairman

THE IBNSINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited)
For the Half-year ended 31st December, 2019

Amount in Taka				
Notes	For the half-year (July 01, 2019 to December 31, 2019)	For the half-year (July 01, 2018 to December 31, 2018)	For the Quarter (October 01, 2019 to December 31, 2019)	For the Quarter (October 01, 2018 to December 31, 2018)
Revenue	3,068,656,223	2,571,471,628	1,534,026,655	1,246,155,832
Cost of goods sold	(1,804,427,683)	(1,522,399,718)	(904,881,172)	(743,909,878)
Gross Profit	1,264,228,541	1,049,071,910	629,145,484	502,245,954
Operating Expenses:				
Administrative expenses	(70,508,180)	(57,861,255)	(36,447,094)	(28,074,936)
Selling & Distribution expenses	(862,250,139)	(729,661,832)	(394,389,236)	(322,802,036)
	<u>(932,758,319)</u>	<u>(787,523,087)</u>	<u>(430,836,330)</u>	<u>(350,876,972)</u>
Operating Profit	331,470,222	261,548,823	198,309,154	151,368,983
Financial charges	(16,708,992)	(6,601,496)	(8,977,635)	(3,249,036)
Other income	782,831	890,125	713,931	839,365
	<u>315,544,061</u>	<u>255,837,452</u>	<u>190,045,450</u>	<u>148,959,312</u>
Workers' P.P. Fund & Welfare Fund	(15,025,908)	(12,182,736)	(9,049,783)	(7,093,301)
Net Profit before tax	300,518,153	243,654,716	180,995,667	141,866,010
Less: Income tax expenses				
Current tax	(75,233,517)	(59,146,175)	(47,205,944)	(34,652,304)
Deferred tax	2,776,018	1,767,504	4,554,365	2,657,192
	<u>(72,457,498)</u>	<u>(57,378,671)</u>	<u>(42,651,578)</u>	<u>(31,995,112)</u>
Net Profit after tax	228,060,654	186,276,045	138,344,089	109,870,898
Other Comprehensive Income:				
Change in fair value of Marketable Securities (AFS)	(133,125)	(91,800)	55,840	66,555
Deferred tax	13,313	9,180	(5,584)	(6,656)
Total other comprehensive income for the period, net of tax	<u>(119,813)</u>	<u>(82,620)</u>	<u>50,256</u>	<u>59,900</u>
Total other comprehensive income for the period 31st December	<u>227,940,842</u>	<u>186,193,425</u>	<u>138,394,345</u>	<u>109,930,798</u>
Earnings per share-basic	7.30	5.96	4.43	3.52


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka
22-Jan-20


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF CHANGES IN EQUITY (Un-Audited)
For the Half-year ended 31st December, 2019

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st July, 2018	284,032,980	4,392,110	(156,978)	938,940,466	1,227,208,578
Total Comprehensive Income/(Loss)	-	-	30,841	336,266,870	336,297,711
Dividend for the year 30 June, 2018 (Cash-30%)	-	-	-	(85,209,894)	(85,209,894)
Dividend for the year 30 June, 2018 (Stock-10%)	28,403,290	-	-	(28,403,290)	-
Balance as at 1st July, 2019	312,436,270	4,392,110	(126,137)	1,161,594,152	1,478,296,395
Total Comprehensive Income/(Loss)	-	-	(119,813)	228,060,654	227,940,842
Dividend for the year 30 June, 2019 (Cash-30%)	-	-	-	(93,730,881)	(93,730,881)
Balance as at 31st December, 2019	312,436,270	4,392,110	(245,950)	1,295,923,925	1,612,506,356


STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Un-Audited)
For the Half-year ended 31st December, 2018

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st January, 2017	258,211,800	4,392,110	289,485,578	552,873,744	1,104,963,232
Reclassification adjustment	-	-	(289,485,578)	24,144,138	(265,341,440)
Total Comprehensive Income/(Loss)	-	-	(156,978)	452,296,714	452,139,736
Dividend for the year 30 June, 2017 (Cash-25%)	-	-	-	(64,552,950)	(64,552,950)
Dividend for the year 30 June, 2017 (Stock-10%)	25,821,180	-	-	(25,821,180)	-
Balance as at 1st July, 2017	284,032,980	4,392,110	(156,978)	938,940,466	1,227,208,578
Total Comprehensive Income/(Loss)	-	-	-	-	-
for the period ended 31st December,	-	-	(82,620)	186,276,045	186,193,425
Dividend for the half year, 2018 (Cash-30%)	-	-	-	(85,209,894)	(85,209,894)
Dividend for the 18th months, 2018 (Stock-10%)	28,403,290	-	-	(28,403,290)	-
Balance as at 31st December, 2018	312,436,270	4,392,110	(239,598)	1,011,603,327	1,328,192,109


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka
22-Jan-20


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF CASH FLOWS (Un-Audited)
For the Half-year ended 31st December, 2019

	Amount in Taka	
	Half-year ended 31.12.2019	Half-year ended 31.12.2018
Cash Flow From Operating Activities:		
Collection from customers & others	3,063,992,872	2,569,956,983
Payment for cost & expenses	(2,855,424,752)	(2,233,065,594)
Miscellaneous Income	764,872	154,513
Cash generated from operations	209,332,992	337,045,902
Income tax paid	(77,229,835)	(36,641,681)
Financial charges	(16,708,992)	(6,601,496)
Net cash flows from operating activities	115,394,165	293,802,725
Cash Flow From Investing Activities:		
Purchase of fixed assets	(429,262,939)	(191,945,620)
Investment	-	(5,000,000)
Profit from bank deposits & investment	17,959	735,612
Net cash used in investing activities	(429,244,980)	(196,210,008)
Cash Flow From Financing Activities:		
Payment of dividend/(paid)	(72,946,614)	(64,776,904)
Long term finance received/(paid) from bank (net)	88,051,590	(2,526,495)
Short term finance received/(paid) from bank (net)	329,216,273	(28,299,985)
Net cash flow from financing activities	344,321,248	(95,603,384)
Increase/(decrease) in cash and cash equivalents	30,470,434	1,989,333
Cash and cash equivalents at the opening	170,953,223	170,014,165
Effect of movements in exchange rate on cash held	(270,185)	(1,188,524)
Cash and cash equivalents at the closing	201,153,472	170,814,974
Net operating cash flow per share (NOCFPS)	3.69	9.40


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka
22-Jan-20


Managing Director


Chairman

The Ibn Sina Pharmaceutical Industry Ltd.
Selected Notes to the Financial Statements (Un-Audited)

For the Half-year ended 31st December, 2019

Selected Explanatory Notes:

01 (a). Basis of Preparation of Financial Statements

These financial Statements have been prepared in line with the accounting policies and methods of computations of the annual financial statements prepared and published for the year ended 30th June, 2019. These interim financial statements includes only selected explanatory notes as deemed appropriate for understanding of these un-audited financial statements.

Sl. No.	IFRS/IAS Title	IFRS	Compliance Status
Compiled from 01 July 2019			
1	Leases	16	Complied
Stoped Compliance from 01 July 2019 as the IAS/IFRS become not applicable			
2	Leases	17	Not Applicable

01 (b). Reporting

This half-yearly financial report has been prepared based on Bangladesh Accounting Standard (BAS)-34 "Interim Financial Reporting".

01 (c). Earnings Per Share (EPS)

Earnings per share has been calculated based on number of shares outstanding for the period ended December 31, 2019 and profit for the same period. The number of shares outstanding for the period was 31,243,627 shares. Earnings per share for the corresponding period of 2018 has also been calculated based on 31,243,627 shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

01.(d) Subsequent events

No Material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

01. (e) Increase in Earnings Per Share (EPS)

As a result of hard work of all employees of the company as well as strong monitoring, guidance and supervision of senior management we have been able to maintain a stable growth in sales revenue and control the costs related with earning revenue. As a result, EPS has been increased during current period over last reporting period.

01 (f). Net Operating cash flow per share (NOCFPS)

The decrease in NOCFPS arose due to the increase in percentage of payment for trade and other payable and advance income tax in the current reporting period.

01. (g) Income Tax

Payment of income tax increase due to increase in revenue and net profit. Advance income tax and income tax payable decrease due to settlement of last year assessment.

01. (h) Purchase of Fixed Assets

Payment for purchases of fixed assets increased due to increased in addition of fixed assets and capital working in process.

01. (i) Profit from bank deposit decrease due to decrease in profit paid by bank.

01. (j) Payment of dividend increase due to payment made for last year cash dividend as approved in AGM .

01.(k) Statement on compliance

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and International Accounting Standard (IAS), the Companies Act, 1994, Securities and Exchange Rules, 1987 and other relevant laws as applicable.

01 (l). Finance charge

Long term loan balance was Tk.213,960,998 and 125,909,408 on 31 December 2019 and 30 June 2019 respectively. Due to increase in long term loan and lease liability as per IFRS 16 finance charge was increased during the reporting period.

01.(m) Increase in Revenue

Due to hard work of all employees of the company as well as strong monitoring, guidance and supervision of senior management sales revenue has been increased during current period over last reporting period.

01.(n) Cash Flow From Investing Activities

Cash flow from investing activities increased during the reporting period due to more payment made for purchases of fixed assets than the same period of last year.

01.(o) The company formed a subsidiary company named "IBN SINA API Limited" to manufacture and trade Active Pharmaceutical Ingredients, Chemicals and related materials. IBN SINA API Limited has got its registration no. C-155137/2019 on 16.09.2019 from the Registrar of Joint Stock Companies and Firms, Bangladesh.

01.(p) As per IAS 34 Para 14 the 2nd quarter financial report has not prepared on a consolidated basis as the company's most recent annual financial statements i.e. for the year 2018-19 were not consolidated.

Previous period figures have been re-arranged to conform to current period's presentation, where considered necessary.

		Amount in Taka	
		As at 31.12.2019	As at 30.06.2019
02. PROPERTY, PLANT AND EQUIPMENT:			
Cost/Revaluation			
Opening Balance		2,410,003,236	2,006,554,756
Addition during the period		81,787,214	403,448,480
		<u>2,491,790,450</u>	<u>2,410,003,236</u>
Accumulated Depreciation			
Opening Balance		725,224,884	596,754,632
Charged during the period		67,864,320	128,470,252
		<u>793,089,205</u>	<u>725,224,884</u>
	Written Down Value (WDV)	<u>1,698,701,245</u>	<u>1,684,778,352</u>
02.1 Capital work-in-progress			
Construction work-in-progress (building)			
Opening Balance		52,696,974	44,776,558
Add: Addition during the year		35,350,705	7,920,416
		<u>88,047,679</u>	<u>52,696,974</u>
Machinery in transit		312,125,020	86,490,505
		<u>400,172,699</u>	<u>139,187,479</u>

Increasing in Capital Working-in-process arose due to addition of construction materials and new machinery which are under installation.

03. RIGHT OF USE OF ASSETS :	57,212,623	-
Less: Depreciation	(12,082,629)	-
Right of use assets arise due implementation of IFRS 16 from 1st July 2019.	<u>45,129,994</u>	<u>-</u>

04. INVESTMENT IN MARKETABLE SECURITIES (FAIR VALUE) 31.12.2019 :

Sl No.	Name of Company Share/Bond	No. of Shares /Bond Held	Face Value Per Share /Bond	Cost of Holding	Average Cost	Quoted Rate Per Share/ Bond as on 31.12.19	Total Market value of shares/ Bond as on 31.12.19	Unrealized Gain/(Loss)
1	Exim Bank Ltd.	44,000	10	428,507	10	10.10	444,400	15,893
2	(IBBL)-in Mudaraba Perpetual Bond (MPB)	4,590	1,000	4,590,000	1,000	937.00	4,300,830	(289,170)
	Total Taka			<u>5,018,507</u>			<u>4,745,230</u>	<u>(273,277)</u>

04.a. Net Gain/(Loss) on Marketable Securities (AFS)

Unrealized Gain/(Loss) Position (Closing)	(273,277)	(140,152)
Deferred tax on gain on marketable securities (AFS)	27,328	14,015
	<u>(245,949)</u>	<u>(126,137)</u>

04.b. Change in fair value of Marketable Securities (AFS)

Unrealized Gain/(Loss) Position (Closing)	(273,277)	(266,220)
Unrealized Gain/(Loss) Position (Opening)	(140,152)	(174,420)
	<u>(133,125)</u>	<u>(91,800)</u>

04.1 INVESTMENT IN ASSOCIATE

Opening balance

Add: Addition during the year

Add/(Less): Share of associate profit/(loss)

Opening Balance

During the year

IBN SINA Consumer Products Ltd.

IBN SINA Consumer Products Ltd. (40% of total share holding)

Increasing in investment in associate arose due to payment for capital subscription.

Amount in Taka	
As at 31.12.2019	As at 30.06.2019
40,000,000	17,750,000
-	22,250,000
40,000,000	40,000,000
(4,597,551)	(2,896,380)
-	(1,701,171)
(4,597,551)	(4,597,551)
35,402,449	35,402,449

05. INVENTORIES:

Raw materials

Packing materials

Work-in-process

Finished goods

Physicians' samples

Pad & literature

Spares & stores

Indirect materials

Printing & stationery

Laboratory chemicals

Material in Transit

136,088,599	131,765,057
69,322,305	68,796,884
59,466,626	56,841,205
141,738,773	136,813,352
2,505,181	2,492,660
1,704,741	1,692,200
146,642	142,100
222,521	214,100
194,872	187,451
164,753	158,332
186,256,476	123,082,013
597,811,489	522,185,354

Materials in transit increase during this quarter due to more materials received from previously opened L/C and introduction of UPAS method of L/C opening.

06. ADVANCES, DEPOSITS & PRE-PAYMENTS :

This is recoverable in cash or for value to be received and consists of as follows :

a. Advances against-

Salary

Expenses/Works

Head office

Sales Centre rent

Motor cycles - To employees

Income Tax

Others

4,364,399	3,447,738
17,741,210	6,069,154
-	11,661,000
8,027,625	8,481,875
9,845,120	7,538,283
165,114,197	197,645,296
506,533	437,382
205,599,084	235,280,728

b. Deposits -

Security money

13,254,250 12,595,627

c. Pre-payments -

Value Added Tax (VAT)

738,788	624,288
738,788	624,288
219,592,122	248,500,644

(a+b+c)

i) Increasing in salary advance arose due to payment of advance against employees salary.

ii) Decreasing in advance income tax arose due to payment for final assessment and regulatory requirement.

iii) Advance for head office rent decrease due to implementation of IFRS 16.

iv) Advance against expense/work increase due to more of payment made to suppliers for supplying goods and services as per contract.

v) Advance against motor cycle increase due to purchasing some motor cycle for marketing field force.

07. CASH & CASH EQUIVALENTS:

Cash in hand & Bank Balance

Imprest Cash

190,250,699	161,203,223
10,902,773	9,750,000
201,153,472	170,953,223

	Amount in Taka	
	As at 31.12.2019	As at 30.06.2019
08. RETAINED EARNINGS :		
Retained Earnings	1,161,594,152	938,940,466
Dividend Paid	(93,730,881)	(113,613,184)
Add : Surplus during the period/year	228,060,654	336,266,870
	<u>1,295,923,925</u>	<u>1,161,594,152</u>
09. NON-CURRENT LIABILITIES:		
Long Term Finance-Net off current maturity	213,960,998	125,909,408
Retirement Benefit Obligation	18,250,155	70,133
	<u>232,211,153</u>	<u>125,979,541</u>

i) Long term finance during the current period increased due to opening some long term from some short term which were initially opened under UPAS systems and after UPAS period maturity these loans were converted into long term loan.

ii) Increasing in retirement benefit obligation arose due to less amount paid to gratuity fund.

09.1 RETIREMENT BENEFIT OBLIGATIONS

Opening balance	70,133	17,252,564
Add: Provision made during the year	44,265,008	37,426,245
Less: Paid during the year	(26,084,986)	(54,608,676)
	<u>18,250,155</u>	<u>70,133</u>

10. DEFERRED TAX LIABILITY:

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS/BAS 12 Income Taxes. Related deferred tax (expense)/income have been disclosed in note 10.1. The components of deferred tax assets and liabilities are given below:

Deferred Tax Calculation As on 31.12.2019

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	1,698,701,245	1,349,753,947	348,947,298	25%	87,236,824
Gratuity	44,335,141	26,084,986	(18,250,155)	25%	(4,562,539)
Unrealized gain on marketable securities	(273,277)	-	(273,277)	10%	(27,328)
For the year 2019-2020	<u>1,742,763,109</u>	<u>1,375,838,933</u>	<u>330,423,866</u>		<u>82,646,958</u>

Deferred Tax Calculation As on 30.06.2019

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	1,684,778,352	1,365,115,149	319,663,203	25%	79,915,801
Gratuity	54,678,809	54,608,676	(70,133)	25%	(17,533)
Unrealized gain on marketable securities	(140,152)	-	(140,152)	10%	(14,015)
For the year 2018-2019	<u>1,739,317,009</u>	<u>1,419,723,825</u>	<u>319,452,918</u>		<u>79,884,252</u>

10.1 Deferred tax (expenses)/income

Closing balance of deferred tax liability	82,646,958	79,884,252
Opening balance of deferred tax liabilities	79,884,252	53,493,557
Total deferred tax expenses	<u>2,762,706</u>	<u>26,390,695</u>
Less: Deferred tax expenses related to other comprehensive income	(13,313)	(9,180)
	<u>2,776,018</u>	<u>26,399,875</u>

11. BANK & OTHER FINANCE :

Short Term Finance	882,424,795	542,029,553
Long Term Finance-Current maturity	12,393,133	23,572,102
	<u>894,817,928</u>	<u>565,601,655</u>

i) Short term finance during the reporting period increase due to opening of various L/Cs for importing various material machineries etc. for companies smooth operation purpose.

12. ACCOUNTS AND OTHER PAYABLES:

Payable for Suppliers
 Accrued Expenses
 Deposits from different parties
 Other Finance
 Income Tax Liability

Amount in Taka	
As at 31.12.2019	As at 30.06.2019
95,651,158	201,468,578
61,457,410	114,236,046
9,542,100	10,059,893
55,841,210	80,348,645
138,069,429	172,596,846
360,561,307	578,710,008

i) Decreasing in payable for suppliers, accrued expenses, deposits from parties arose due to more amount paid to suppliers, expenses and repayment the party who provide deposits.

ii) Decreasing in income tax liability arose as annual income tax assessment has completed assessment .

13. COST OF GOODS SOLD :

Materials
 Factory Overhead
 Depreciation

Amount in Taka	
For the half-year (July 01, 2019 to December 31, 2019)	For the half-year (July 01, 2018 to December 31, 2018)
1,462,929,284	1,219,929,284
285,497,980	252,914,624
56,000,419	49,555,810
1,804,427,683	1,522,399,718

i) Cost of materials, expenses incurred for factory overhead and depreciation expense during the reporting period increased due to increase in goods sold, increase in production and addition of fixed assets respectively .

14. ADMINISTRATIVE EXPENSES :

Salary, wages & Allowances
 Repairs & Maintenance
 Travelling & Conveyance
 AGM, Fees and Others
 Depreciation
 Other Expenses

37,176,159	34,618,458
3,437,789	3,301,898
2,201,664	2,120,225
1,456,855	1,384,625
17,262,961	3,485,263
8,972,752	12,950,786
70,508,180	57,861,255

i) Salary, wages & allowance increase due to increase in manpower, gratuity payment and salary revision.

ii) Depreciation expense during the reporting period increased due to addition of fixed assets and implementation of IFRS 16.

iii) Other expense decrease during the reporting period due to strong management supervision and effort from all levels of employee:

15. SELLING & DISTRIBUTION EXPENSES :

Salary, wages & Allowances
 Travelling & Conveyance
 Market Survey & Research and Product development
 Field personnel expenses
 Sample, Literature & Promotional Expenses
 Delivery Expenses
 Depreciation
 Other Expenses

523,108,855	423,151,514
2,139,739	2,048,262
1,559,229	1,465,733
97,726,758	93,086,002
57,533,322	54,234,144
69,793,793	65,832,572
6,683,570	5,819,591
103,704,873	84,024,014
862,250,139	729,661,832

i) Salary, wages & allowance increase due to increase in manpower, gratuity payment and salary revision.

ii) Delivery expense during the reporting period increased due to increase in fuel and gas cost and vehicles rent cost.

iii) Field personnel expense and Sample etc. increase due to increase of field personnel movement in order to increase sales.

iv) Depreciation expense during the reporting period increased due to addition of fixed assets and implementation of IFRS 16.

Amount in Taka	
For the half-year (July 01, 2019 to December 31, 2019)	For the half-year (July 01, 2018 to December 31, 2018)

16.1 Current tax

This represents estimated Income Tax liability for the year as follows:

Profit before tax	300,518,153	243,654,716
Add: Accounting depreciation	67,864,320	58,860,664
Less: Tax depreciation	(85,358,244)	(80,990,304)
Add: Gratuity provision	44,265,008	26,380,665
Less: Gratuity paid	(26,084,986)	(10,132,518)
Unrealized loss on foreign exchange	(270,185)	(1,188,524)
Business Income	300,934,067	236,584,699
Income tax on business income @25%	75,233,517	59,146,175

16.2 Reconciliation of net profit with cash flows from operating activities

Profit before tax (PBT)	300,518,153	243,654,716
Adjustments:		
Depreciation	67,864,320	58,860,664
Unrealized foreign exchange loss	(270,184.52)	(1,188,524.40)
Change In operating assets		
Increase in inventory	(75,626,135)	(2,486,658)
Increase in accounts receivables	(3,880,520)	(624,520)
Decrease in advances, deposits and prepayments	(3,622,578)	157,297
Increase/(decrease) in trade and other payable	(94,227,593)	9,915,214
Increase/(decrease) in retirement benefit obligation	18,180,022	26,380,665
Income Tax paid	(77,229,835)	(36,641,681)
Finance charge paid	(16,708,992)	(6,601,496)
	114,996,659	291,425,677
	115,394,165	293,802,725

16.3 Earning per share (EPS)

Earnings attributable to the ordinary shareholders (net profit after tax)	228,060,654	186,276,045
Number of ordinary shares outstanding during the year	31,243,627	31,243,627
	7.30	5.96

16.4 Net assets value per share (NAV)

Net Assets value	1,612,506,356	1,478,296,395
Number of ordinary shares outstanding during the year	31,243,627	31,243,627
	51.61	47.32

16.5 Net Operating cash flow per share (NOCFPS)

Net cash provided by operating activities	115,394,165	293,802,725
Divided by number of ordinary shares outstanding during the year	31,243,627	31,243,627
	3.69	9.40



Chief Financial Officer


Company Secretary


Director

Dated, Dhaka
22-Jan-2020


Managing Director


Chairman